neurology

News

Graphical representation of Brainshuttle antibody at the blood-brain barrier

Roche preps phase 3 for 'Brainshuttle' Alzheimer's drug

Buoyed by data from a phase 1b/2a trial, Roche has said it plans to start a phase 3 programme for an Alzheimer's drug from its Brainshuttle programme.

News

Prof Vanessa Raymont of the University of Oxford

UK sets aside £2m for digitally-enhanced dementia tests

The UK is providing £2m in funding to allow digital assessment to be added to a highly-anticipated trial of blood tests for diagnosing dementia.

News

End of the line for Cassava's troubled Alzheimer's programme

The saga of Cassava Sciences' development of Alzheimer's disease therapy simufilam has come to its dismal end.

News

Augustine decloaks with $85m for nerve disease programme

Belgian start-up Augustine raises €78m ($85m) in first-round funding for HDAC6 inhibitors headed by a candidate for Charcot-Marie-Tooth disease.

News

Bayer gains ground in two-fronted Parkinson's offensive

Bayer's cell therapy for Parkinson's disease is on the brink of a phase 3 trial, while its gene therapy has started phase 2 testing.

News

Algorithm spots common sleep disorder linked to dementia

An AI algorithm can help detect REM sleep behaviour disorder, which affects millions of people and is a warning signal for neurological diseases.

Roche preps phase 3 for 'Brainshuttle' Alzheimer's drug

UK sets aside £2m for digitally-enhanced dementia tests

End of the line for Cassava's troubled Alzheimer's programme

Augustine decloaks with $85m for nerve disease programme

Bayer gains ground in two-fronted Parkinson's offensive

Algorithm spots common sleep disorder linked to dementia

NHS to offer Wegovy to a million more people in England

Using AI-driven synthetic personas to take your insights fur...

neurology

Editor's Picks